Tallian K B, Nahata M C, Tsao C Y
Ohio State University, Columbus 43210, USA.
Ann Pharmacother. 1998 Mar;32(3):349-61. doi: 10.1345/aph.16245.
To provide a review of the mechanism of action, clinical efficacy, adverse effects, drug interactions, and therapeutic considerations associated with the use of a ketogenic diet to manage patients with intractable seizures.
A MEDLINE search from January 1966 to the present and relevant articles from journals were reviewed.
The ketogenic diet has been used as a treatment modality since the early 1920s to control intractable seizures. The exact mechanism of action is unknown. Overall, uncontrolled clinical studies have reported that approximately one-third of patients with intractable seizures have become seizure-free on the ketogenic diet. Common adverse events attributed to the diet include dehydration, gastrointestinal symptoms, hypoglycemia, as well as carnitine and vitamin deficiencies. Cognitive effects, hyperlipidemia, impaired neutrophil function, urolithiasis, optic neuropathy, osteoporosis, and protein deficiency may also occur in some patients. Carbohydrate content and drug formulation in the selection of medications while on the diet are important. Acetazolamide, phenobarbital, and valproic acid have been reported to interact with the ketogenic diet. Medications that cause carnitine deficiency or influence carbohydrate metabolism should also be used with caution. The carbohydrate content of drugs in various therapeutic classes is presented to aid in the selection of the most appropriate drug and formulation for patients on the ketogenic diet. The success of the diet in controlling intractable seizures is related to the patient's close adherence to the diet. Minimizing carbohydrate ingestion from medications along with a multidisciplinary team approach to the selection and monitoring of the diet are important to the success of the ketogenic diet in controlling seizures.
The ketogenic diet has shown promising results in controlling intractable seizures; however, carefully controlled clinical trials are needed to better assess the efficacy of the diet during its use and after discontinuation.
综述生酮饮食用于治疗难治性癫痫患者的作用机制、临床疗效、不良反应、药物相互作用及治疗注意事项。
回顾了1966年1月至今的MEDLINE检索结果以及期刊上的相关文章。
自20世纪20年代初以来,生酮饮食一直被用作一种治疗方式来控制难治性癫痫发作。确切的作用机制尚不清楚。总体而言,非对照临床研究报告称,约三分之一的难治性癫痫患者采用生酮饮食后癫痫发作停止。归因于该饮食的常见不良事件包括脱水、胃肠道症状、低血糖以及肉碱和维生素缺乏。一些患者还可能出现认知影响、高脂血症、中性粒细胞功能受损、尿路结石、视神经病变、骨质疏松和蛋白质缺乏。饮食期间选择药物时的碳水化合物含量和药物剂型很重要。据报道,乙酰唑胺、苯巴比妥和丙戊酸与生酮饮食存在相互作用。导致肉碱缺乏或影响碳水化合物代谢的药物也应谨慎使用。列出了各类治疗药物的碳水化合物含量,以帮助为生酮饮食的患者选择最合适的药物和剂型。该饮食在控制难治性癫痫发作方面的成功与患者严格坚持饮食有关。尽量减少药物中的碳水化合物摄入量以及采用多学科团队方法来选择和监测饮食,对于生酮饮食成功控制癫痫发作很重要。
生酮饮食在控制难治性癫痫发作方面已显示出有前景的结果;然而,需要进行严格对照的临床试验,以更好地评估该饮食在使用期间及停用后的疗效。